While the Buy rating reaffirms confidence in Guardant Health's prospects, the reduction in the price target may reflect a more conservative outlook on the company's valuation or market conditions. This mixed signal could lead to a neutral short-term impact on the stock as investors digest both the continued endorsement and the lowered expectations.